Literature DB >> 10340386

The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun.

V Dejong1, A Degeorges, S Filleur, S Ait-Si-Ali, A Mettouchi, P Bornstein, B Binétruy, F Cabon.   

Abstract

Thrombospondin 1 (TSP1) is known for its significant anti-angiogenic properties. In a previous study, we have shown that transient or stable overexpression of the transcription factor c-Jun, in rat fibroblasts, leads to repression of TSP1. We now demonstrate that the c-Jun-induced repression of TSP1 does not occur directly and does not require binding of c-Jun to the TSP1 promoter. Instead, repression involves a factor secreted by c-Jun-overexpressing cells. This secreted factor triggers a signal transduction pathway from the membrane to the nucleus, and these signals lead to the binding of the product of the Wilms' tumor suppressor gene, WT1, to the -210 region of the TSP1 promoter. This region binds WT1 and SP1, but not EGR1, although its sequence fits the consensus binding site for this transcription factor. WT1 overexpression in transfected cells inhibits endogenous TSP1 gene expression and TSP1 transcription in experiments using TSP1 promoter-reporter constructs. The WT1 - KTS isoform is more active in repressing TSP1 transcription than WT1 + KTS, while EGR1 is inactive. Enhancement of WT1 binding to DNA in response to c-Jun does not require de novo protein synthesis. The above mechanism for TSP1 repression could apply to other genes, thus coordinating their regulation in the vicinity of a c-Jun-overexpressing cell. We conclude that WT1, which was discovered as a result of its tumor suppressor properties, may also possess oncogenic characteristics in the c-Jun transformation process, and thus repress the anti-angiogenic protein, TSP1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340386     DOI: 10.1038/sj.onc.1202654

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA.

Authors:  A Janz; C Sevignani; K Kenyon; C V Ngo; A Thomas-Tikhonenko
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

2.  In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.

Authors:  S Filleur; O V Volpert; A Degeorges; C Voland; F Reiher; P Clézardin; N Bouck; F Cabon
Journal:  Genes Dev       Date:  2001-06-01       Impact factor: 11.361

3.  Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.

Authors:  S A Kim; S J Um; J H Kang; K J Hong
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

4.  p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers.

Authors:  Prema Sundaram; Stacy Hultine; Lauren M Smith; Michael Dews; Jamie L Fox; Dauren Biyashev; Janell M Schelter; Qihong Huang; Michele A Cleary; Olga V Volpert; Andrei Thomas-Tikhonenko
Journal:  Cancer Res       Date:  2011-10-25       Impact factor: 12.701

Review 5.  Invoking the power of thrombospondins: regulation of thrombospondins expression.

Authors:  Olga Stenina-Adognravi
Journal:  Matrix Biol       Date:  2014-02-25       Impact factor: 11.583

Review 6.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Authors:  Y Mirochnik; A Kwiatek; O V Volpert
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

7.  Differentiation of human fetal multipotential neural progenitor cells to astrocytes reveals susceptibility factors for JC virus.

Authors:  Michael W Ferenczy; Kory R Johnson; Leslie J Marshall; Maria Chiara Monaco; Eugene O Major
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

8.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Authors:  Yu-Wen Zhang; Yanli Su; Olga V Volpert; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

9.  The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy.

Authors:  Lesley A Simpson; Emily A Burwell; Kida A Thompson; Samira Shahnaz; Allen R Chen; David M Loeb
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

10.  Beta1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1.

Authors:  Hira Lal Goel; Loredana Moro; Joanne E Murphy-Ullrich; Chung-Cheng Hsieh; Chin-Lee Wu; Zhong Jiang; Lucia R Languino
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.